Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D

Bausch + Lomb has appointed Thomas J. Appio as interim CEO, effective immediately, following the mutual agreement for Brent Saunders to depart the company. The company and its parent, Bausch Health, expect to raise their full-year 2026 adjusted EBITDA guidance, excluding acquired IPR&D, based on preliminary third-quarter results. Appio, who has been with Bausch + Lomb since 2010 and served as CEO of Bausch Health since 2022, is expected to leverage his experience to lead the company’s next phase of growth.